

Genomic Response Report

Lifetime Sciences
4037 Rural Plains Circle, Suite 150 • Franklin, Tennessee 37064
Phone: (615) 550-5880 • Fax: (615) 550-5889
Laboratory Director: Dr. Terry Pearson, M.D.
CLIA ID Number: 44D-2031868
www.lifetimesciences.com/

Lifetime Sciences MyPGtLive

Individualized, additional therapeutic decision support information based on PATIENT TEST's genetics, drug regimen, indications, demographics, and lifestyle indicators are available at Lifetime Sciences MyPGtLive via this secured URL: <https://app.mypgtlive.com?token=prompt>



PGtLive Key: AG7543KEH
Sample ID: RD000-000-022

Patient: TEST, PATIENT
Date of Birth: Oct 10, 1950
Gender: Female


Physician: Thomas Brewer
Practice: The Testing Center for Test Excellence

Date Collected: Nov 28, 2018
Specimen type: Oral Rinse Kit
Sample ID: RD000-000-022

Current Regimen Risk Chart

This chart summarizes the various risk factors associated with each medication entered into Lifetime Sciences MyPGtLive for PATIENT TEST. The length of each colored segment represents the relative contribution of a risk category (detailed in the below legend) to the overall risk associated with the use of a medication. For further information, consult the [Current Regimen Risk Details Pg. 3](#) section.

For further assistance in choosing alternative medications to reduce this patient's risk, use the modeling tool at <https://app.mypgtlive.com?token=prompt>.



RD000-000-022 - TEST, PATIENT - Reported Dec 10, 2018 - DRAFT

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history and current treatment regimen.

Genetic Summary

Gene	Result	Activity †
ANKK1	A A	Altered function
ApoE	ε3 ε3	See ApoE Genotype Info.
ATM	A C	Increased likelihood of treatment success when taking metformin
COMT(Val158Met)	G A	Uncertain function
CYP1A2	*1L *1W	Altered function
CYP2B6	*1A *6	Intermediate metabolizer
CYP2C19	*2 *17	Multiple statuses; see per-drug detail
CYP2C9	*1 *1	Extensive metabolizer
CYP2D6	*2 *17	Extensive metabolizer
CYP3A4	*1A *1B	Uncertain
CYP3A5	*3C *6; or *3A *6	Poor metabolizer
CYP4F2	*1 *1	Extensive metabolizer
Factor V Leiden	Normal	See Thrombosis Profile
GRIK4	T C	Uncertain function
HLA-B*1502	WT WT	WT
HTR2A	G G	Altered function
MTHFR (A1298C)	Normal	See Thrombosis Profile
MTHFR (C677T)	Normal	See Thrombosis Profile
OPRM1(A118G)	A A	Normal function
Prothrombin (F2)	Normal	See Thrombosis Profile
SLCO1B1	*1 *1	Normal liver uptake activity
TPMT	*1 *1	Extensive metabolizer
VKORC1	*1 *1	Normal (with respect to Warfarin)

Genetic Summary Information

† When multiple activities are listed, check information in Medication Report Details ([Pg. 9](#)) for specific medication of interest. *Uncertain = No known diplotype/result (name) or activity for this combination of genetic variants; Uninterpretable Genotype.*

Current Regimen Risk Detail

Severe Risks

Genetic warning for Plavix (Clopidogrel Bisulfate)

Individuals with intermediate metabolizer status are at an increased risk therapeutic failure due to reduced activation of the prodrug and low plasma concentrations of the active compound. Clopidogrel is not recommended.

American Geriatric Society guidelines

The following products appear on the American Geriatric Society's Beers Criteria for Potentially Inappropriate Medication Use in Older Adults:

- Aspirin 500mg Oral tablet

Black box warning for Coumadin, Jantoven (Warfarin) and bleeding

Major Risks

**Contact clientsupport@lifetimesciences.com
if you are interested in seeing a full**

sample report. Coumadin, Jantoven (Warfarin) causes additive increased risk of bleeding with Bayer Extra Strength, Bufferin Extra Strength

- use combination with caution
- monitor for evidence of bleeding
- monitor international normalized ratio (INR) or prothrombin time

Co-administration of aspirin and warfarin is associated with an increased risk of bleeding. Consider alternate therapy for aspirin for pain or fever. If co-use, monitor the patient for signs and symptoms of bleeding.

Moderate Risks

Genetic warning for Coumadin, Jantoven (Warfarin)

Individuals with this combination of alleles may benefit from an increased dose of Warfarin. The FDA table recommends a therapeutic dose of 5-7 mg/day.